In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...

FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...

Dr. Liang previously worked at Novo Nordisk, where he lead global clinical development and regulatory submission for ...

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Four long-acting antibodies will be jointly advanced, targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13, extending type 2 ...

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business ...

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...

Novartis secured an exclusive worldwide license to Abogen’s Abo2203 and options on additional RNA-platform programs, positioning mRNA-encoded biologic expression as a scalable autoimmune therapeutic ...

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand ...

FHD-909 is an oral, first-in-class allosteric small molecule selectively inhibiting SMARCA2 (BRM) ATPase over SMARCA4 (BRG1), both central catalytic subunits of BAF chromatin-remodeling complexes.